Tenecteplase

Generic Name: Tenecteplase

Brand Names: Metalyse, Tnkase

Drug Type: Biotech

Chemical Formula: -

CAS Number: 191588-94-0

Unique Ingredient Identifier: WGD229O42W

Background: Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease doma...

Indication: 用于溶栓治疗。

Associated Conditions: Cardiovascular Mortality

Associated Therapies: -

Clinical Trials

Intra-arterial Tenecteplase During First Thrombectomy Attempt for Acute Stroke (BRETIS-TNK II)

Phase 3

Recruiting

Conditions: Stroke, Ischemic

Interventions: Drug: Tenecteplase

First Posted Date: 2022-12-20

Last Posted Date: 2024-07-09

Lead Sponsor: General Hospital of Shenyang Military Region

Target Recruit Count: 372

Registration Number: NCT05657444

Locations: 🇨🇳
General Hospital of Northern Theater Command, ShenYang, China

Rescue Thrombolysis for Medium Vessel Occlusion (RESCUE-TNK)

Phase 2

Recruiting

Conditions: Stroke, Ischemic

Interventions: Drug: Tenecteplase

First Posted Date: 2022-12-20

Last Posted Date: 2024-07-09

Lead Sponsor: General Hospital of Shenyang Military Region

Target Recruit Count: 80

Registration Number: NCT05657470

Locations: 🇨🇳
General Hospital of Northern Theater Command, ShenYang, China

Tenecteplase Compared to Alteplase for Patients With Large Vesel Oclusion Suspicion Before Thrombectomy

Phase 3

Recruiting

Conditions: Acute Ischemic Stroke

Interventions: Drug: Tenecteplase

First Posted Date: 2022-11-25

Last Posted Date: 2022-11-25

Lead Sponsor: Hospital Universitari Vall d'Hebron Research Institute

Target Recruit Count: 500

Registration Number: NCT05626972

Locations: 🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain

Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions

Phase 3

Recruiting

Conditions: Ischemic Stroke

Interventions: Drug: Tenecteplase

First Posted Date: 2022-08-12

Last Posted Date: 2024-11-26

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 156

Registration Number: NCT05499832

Locations: 🇫🇮
University Hospital Helsinki, Helsinki, Finland
🇦🇹
LKH-Universitätsklinikum Graz, Graz, Austria
🇦🇹
Medizinische Universität Innsbruck, Innsbruck, Austria

and more 36 locations

Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-II）

Phase 2

Conditions: Acute Ischemic Stroke

Interventions: Drug: Alteplase
Drug: Tenecteplase

First Posted Date: 2022-03-16

Last Posted Date: 2022-03-31

Lead Sponsor: Beijing Tiantan Hospital

Target Recruit Count: 225

Registration Number: NCT05281549

Locations: 🇨🇳
Huai'an Second People's Hospital, Huai'an, Jiangsu, China
🇨🇳
Tangshan Gongren Hospital, Tangshan, Hebei, China
🇨🇳
Mei He Kou Central Hospital, Meihekou, Jilin, China

and more 25 locations

Randomization to Endovascular Treatment Alone or Preceded by Systemic Thrombolysis With Tenecteplase in Ischemic Stroke

Phase 3

Recruiting

Conditions: Stroke, Ischemic
Stroke, Acute

Interventions: Drug: Placebo
Drug: Tenecteplase

First Posted Date: 2022-01-20

Last Posted Date: 2024-01-30

Lead Sponsor: Hospital Moinhos de Vento

Target Recruit Count: 390

Registration Number: NCT05199194

Locations: 🇧🇷
Hospital das Clínicas Botucatu, Botucatu, Brazil
🇧🇷
Hospital das Clínicas da UFPR, Curitiba, Brazil
🇧🇷
Hospital Sao Paulo, São Paulo, Brazil

and more 10 locations

Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke

Phase 2

Recruiting

Conditions: Basilar Artery Occlusion

Interventions: Drug: Standard Care (which may include intravenous Alteplase)
Drug: Tenecteplase

First Posted Date: 2021-11-03

Last Posted Date: 2023-12-06

Lead Sponsor: University of Melbourne

Target Recruit Count: 688

Registration Number: NCT05105633

Locations: 🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺
Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia
🇦🇺
Liverpool Hospital, Sydney, New South Wales, Australia

and more 10 locations

A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity

Phase 3

Completed

Conditions: Stroke

Interventions: Drug: tenecteplase
Drug: alteplase

First Posted Date: 2021-06-07

Last Posted Date: 2024-12-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1489

Registration Number: NCT04915729

Locations: 🇨🇳
Inner Mongolia Baogang Hospital, Baotou, China
🇨🇳
Beijing Chao-Yang Hospital, Beijing, China
🇨🇳
Beijing Tsinghua Changgung Hospital, Beijing, China

and more 52 locations

MRI-guided thrOmbolysis for Stroke bEyond Time Window by TNK

Phase 4

Completed

Conditions: Stroke

Interventions: Drug: Tenecteplase

First Posted Date: 2021-02-12

Last Posted Date: 2022-08-02

Lead Sponsor: General Hospital of Shenyang Military Region

Target Recruit Count: 80

Registration Number: NCT04752631

Locations: 🇨🇳
Department of Neurology, General Hospital of Northern Theater Command, Shenyang, China

Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events(TRACE)

Phase 2

Completed

Conditions: Acute Ischemic Stroke

Interventions: Drug: TNK-tPA

First Posted Date: 2020-12-21

Last Posted Date: 2020-12-21

Lead Sponsor: Beijing Tiantan Hospital

Target Recruit Count: 240

Registration Number: NCT04676659

Locations: 🇨🇳
ZhongShan Hospital ,FuDan University, Shanghai, Shanghai, China
🇨🇳
1st Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan, China
🇨🇳
SiChuan University HuaXi Hospital, Chengdu, Sichuan, China

and more 21 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy